LISTEN IN NOW as a general cardiologist, surgeon, and interventionalist delve into the latest evidence—including the Evolut™ TAVR 5-Year Low Risk data and SMART Trial 2-Year update—to guide appropriate treatment decisions for patients with severe symptomatic aortic stenosis. TAVR or SAVR? Gain actionable real world insights regarding therapy considerations and lifetime management strategies in the low risk and/or small annulus patient population. The discussion also will explore why achieving a lower mean gradient is especially important for active individuals— backed by evidence and experience.
What You'll Learn:
- Exploring clinical evidence to highlight valve performance of EvolutTM TAVR
- Understanding why post-TAVR coronary access has become more feasible with the EvolutTM TAVR and less of a concern for patients
- Explaining how advancements and technique have minimized pacemaker concerns post-TAVR
- Focusing on which valves offer excellent hemodynamic performance and less bioprosthetic valve dysfunction (BVD) and why that is important for patient’s long term
- Guiding shared decision-making discussions with patients who may be younger, and/or have a small annulus, especially in women
- Discussing therapy options with patients without overwhelming them
Why This Matters:
Through data-driven insights on selecting the optimal therapy and TAVR valve for each patient, we’re equipping cardiologists and heart teams with the essential tools and strategies to pursue sustained hemodynamic valve performance, reduce the risk of bioprosthetic valve dysfunction, and optimize both short and long-term outcomes for AS patients.
Who Should Watch:
- Diagnosing General Cardiologists
- Structural Heart Teams
- Cardiology and Heart Failure Administrators
- Cardiovascular Service Line Directors
- Advanced Practice Providers
- Hospital and Health System C-Suite: COOs, CEOs, CFOs
Panel:
Kathryn Berlacher, MD |
Michael Reardon, MD |
Angela Lowenstern, MD |
